We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
Lexology logo






  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 18

Indian Supreme Court rules for cancer pills patent to be made available to generics

  • King & Wood Mallesons
  • -
  • India
  • -
  • April 29 2013

Earlier this month, the Supreme Court of India dismissed an appeal brought by Novartis against the Indian Intellectual Property Board's 2009 decision

Experimental evidence comply with the rules or risk inadmissibility

  • King & Wood Mallesons
  • -
  • Australia
  • -
  • March 22 2013

By refusing to allow Generic Health to adduce experimental evidence in a patent case currently being heard in the Federal Court, Justice Jagot has

Blockbuster drug goes bust? The Federal Court finds three AstraZeneca patents relating to Crestor (rosuvastatin) invalid

  • King & Wood Mallesons
  • -
  • Australia
  • -
  • March 7 2013

In an important decision handed down on Tuesday, Justice Jagot of the Federal Court held that three patents relating to the blockbuster drug Crestor

Australian court decides important gene patenting question isolated genetic material patentable subject matter

  • King & Wood Mallesons
  • -
  • Australia
  • -
  • February 15 2013

Earlier today, the Federal Court rejected a claim brought by Cancer Voices Australia that isolated genetic material (DNA or RNA) that is naturally

Government expropriation of patents more drugs to combat HIVAIDS and Hep B in Indonesia

  • King & Wood Mallesons
  • -
  • Indonesia
  • -
  • October 24 2012

On 3 September 2012, the Indonesian Government issued a “government use” decree, a type of compulsory licence, in relation to seven patent-protected HIVAIDS and Hepatitis B medicines in Indonesia

Compulsory licenses for emergency drugs for developing countries

  • King & Wood Mallesons
  • -
  • Australia, Global
  • -
  • October 24 2012

IP Australia has released an “Exposure Draft” of the Intellectual Property Laws Amendment Bill 2012 (“Bill”

Government announces review into pharmaceutical patents

  • King & Wood Mallesons
  • -
  • Australia
  • -
  • October 18 2012

Further to our previous post about proposed reforms to the patent law, the Australian Government has announced another review this time of pharmaceutical patents

India Supreme Court to rule on evergreening clause

  • King & Wood Mallesons
  • -
  • India
  • -
  • September 14 2012

"Evergreening" refers to various legal and commercial strategies employed by companies to maximise profits and frustrate competition, such as making relatively minor changes to existing drugs with soon-to-expire patents in order to obtain further patent protection

Are genes patentable? US Court of Appeals says “yes” for the second time

  • King & Wood Mallesons
  • -
  • USA
  • -
  • August 23 2012

In March this year, the US Court of Appeals was ordered by the US Supreme Court to reconsider its decision in Association for Molecular Pathology v Myriad Genetics

European Commission ups the cost of paying for delay

  • King & Wood Mallesons
  • -
  • Australia, European Union, USA
  • -
  • August 13 2012

On 25 July 2012, the EC alleged that Danish pharmaceutical company Lundbeck violated EU antitrust rules by colluding to prevent other pharma companies from marketing generic versions of its best-seller antidepressant, citalopram

Current Search

Suggested Facets

Author

Jurisdiction

Workarea

© Copyright 2006-2013 Globe Business Publishing Ltd | Cookies | Disclaimer | Privacy policy